Burt DS - Search Results

1

Protollin: a novel adjuvant for intranasal vaccines.

Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Among authors: burt ds. Vaccine. 2004 Sep 9;22(27-28):3691-7. doi: 10.1016/j.vaccine.2004.03.035. Vaccine. 2004. PMID: 15315848

2

C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.

Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ. Cyr SL, et al. Vaccine. 2007 Apr 20;25(16):3228-32. doi: 10.1016/j.vaccine.2007.01.037. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17374422

3

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ. Cyr SL, et al. Vaccine. 2007 Jul 20;25(29):5378-89. doi: 10.1016/j.vaccine.2007.05.004. Epub 2007 May 24. Vaccine. 2007. PMID: 17561317

4

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Among authors: burt ds. Vaccine. 2003 Sep 8;21(25-26):3706-12. doi: 10.1016/s0264-410x(03)00387-6. Vaccine. 2003. PMID: 12922101

5

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.

Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, Ward BJ. Chabot S, et al. Among authors: burt ds. Vaccine. 2005 Feb 3;23(11):1374-83. doi: 10.1016/j.vaccine.2004.09.010. Vaccine. 2005. PMID: 15661386

6

Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.

Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, Lowell GH, Burt DS. Jones T, et al. Among authors: burt ds. Vaccine. 2006 Mar 6;24(10):1625-32. doi: 10.1016/j.vaccine.2005.09.052. Epub 2005 Oct 7. Vaccine. 2006. PMID: 16243411

7

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.

Hu MC, Jones T, Kenney RT, Barnard DL, Burt DS, Lowell GH. Hu MC, et al. Among authors: burt ds. Vaccine. 2007 Aug 21;25(34):6334-40. doi: 10.1016/j.vaccine.2007.06.017. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17640780 Free PMC article.

8

TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.

Cyr SL, Angers I, Guillot L, Stoica-Popescu I, Lussier M, Qureshi S, Burt DS, Ward BJ. Cyr SL, et al. Among authors: burt ds. Vaccine. 2009 Jan 14;27(3):421-30. doi: 10.1016/j.vaccine.2008.10.073. Epub 2008 Nov 14. Vaccine. 2009. PMID: 19013492

9

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.

Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Félix N, White GL, Lowell GH, Burt DS. Plante M, et al. Among authors: burt ds. Vaccine. 2001 Oct 12;20(1-2):218-25. doi: 10.1016/s0264-410x(01)00268-7. Vaccine. 2001. PMID: 11567767

10

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. Treanor J, et al. Vaccine. 2006 Jan 16;24(3):254-62. doi: 10.1016/j.vaccine.2005.07.088. Epub 2005 Aug 15. Vaccine. 2006. PMID: 16129526 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters